Urine drug testing is an important tool that is commonly used to assess patient compliance with prescription regimens. Point-ofcollection immunoassay devices allow for timely availability of laboratory test results to guide therapy during the same office visit. Two waived immunoassay-based urine drug screen cups were evaluated in this study. The NexScreen cup and the DrugCheck Waive RT cup claim to detect 10-12 drug classes of commonly used and/ or abused drugs. This study included a sensitivity and precision challenge with 4-6 replicates at concentrations 0 -150% of the manufacture's claimed cutoff, using drug-free urine spiked with purified reference standards. The stability of test results was evaluated by reading the results at intervals between five and 1,440 min. Specificity was evaluated by parallel comparison of pooled patients' specimens, representing 56 patients and 41 known drug compounds. When comparing results to validated liquid chromatographymass spectrometry results, false positives were observed in the NexScreen cups for benzodiazepine, methamphetamine, methadone, opiates and tricyclic antidepressant tests, but there were no false negatives. The DrugCheck Waive RT cups showed false negative results for barbiturates and opiates, but no false positives. Overall, the NexScreen cup demonstrated better sensitivity than claimed, whereas the sensitivity of the DrugCheck Waive RT cup did not meet claims.
Introduction
According to the 2010 National Survey on Drug Use and Health (NSDUH), an estimated 22.1 million people aged 12 or older have been classified with substance dependence or abuse (1). It is believed that drug abuse has significant impact on medical costs, job performance, traffic and work-related accidents. Each year, drug abuse results in approximately 40 million serious illnesses or injuries among people in the United States. Prescription drug misuse has become epidemic in the United States, contributing to drug trafficking, safety concerns and addiction. Efficient and rapid screening methods are imperative to detect inappropriate drug use among patients that are managed chronically with a scheduled drug, such as oxycodone.
A variety of specimens can be assayed for drugs; for example, urine, blood, sweat, saliva and hair. Urine remains the most commonly collected and tested specimen for drugs of abuse because of the ease of collection, relatively high drug and metabolite concentrations and availability of a variety of testing methods. Urine drug testing is also a non-invasive way to screen for compliance with prescription drugs. It can provide information for tracking patient compliance and exposing possible drug misuse. Immunoassay is the most common method used for initial screening. The use of on-site ( point-of-collection) devices as an aid in clinical diagnosis has long been recognized as a mechanism to allow rapid generation of biomedical results.
On-site immunoassay devices are now widely marketed, but they differ in performance claims and regulatory oversight. Devices such as urine cups that integrate the testing technology with the collection container are particularly convenient for office-based testing when regulatory requirements are minimal. The primary advantage of these devices is the rapidity of laboratory test results, which are available within a few minutes to directly impact patient care decisions during the same office visit. Such devices do not require sophisticated instrumentation or extensively trained personnel to perform the analyses, and many have been assigned waived regulatory status. Waived devices may be performed simply and accurately by nonlaboratory health care workers, with minimum training. Waived tests include test systems cleared by the Food and Drug Administration (FDA) for home use and those tests approved for waiver under the criteria of the Clinical Laboratory Improvement Amendments of 1988 (CLIA).
The purpose of this study was to evaluate the performance of two waived-status immunoassay based urine drug screen cups, the NexScreen cup and the DrugCheck Waive RT cup. Specifically evaluated were the ability for the drug screen cups to detect purified reagent standards for each drug class, at concentrations above and below the cutoffs published by the manufacturers; the stability of the results over time; the ability of the cup to accurately identify multiple drugs in patient urine; and the effect of potential cross reacting, interfering compounds.
Experimental
On-site testing device The NexScreen cup and the DrugCheck Waive RT cup are designed for drug testing. Both cups are cleared by the FDA for home use, and have waived status as per CLIA. The NexScreen cups (Lots 1110020 and 1111027) were purchased from Amedica Biotech (Hayward, CA). The DrugCheck Waive RT cups (Lots J12698 and F11864) were purchased from Express Diagnostics (Blue Earth, MN). The NexScreen cup required 30 mL of urine and the DrugCheck Waive RT cup required 75 mL of urine to perform the test.
Drug detection is based on the principle of competitive immunochemical reaction. The nitrocellulose strips are impregnated with a chemically labeled drug conjugate in the test region, which is adjacent to a pad containing colored antibodycolloidal gold conjugate. During the test, the urine sample migrates upward and hydrates the antibody-colloidal gold conjugate. The mixture then chromatographically migrates along the membrane by capillary action to the immobilized drug conjugate band on the test region. If the cross-reacting drug analyte is present in the urine, it competes with the drug conjugate for a limited number of antibody binding sites. In the absence of drugs in the urine sample, the colored antidrug antibody chromatographically migrates to the immobilized drug conjugated zone to from a visible line as the antibody complexes with the drug conjugate. When a sufficient concentration of drug analyte is present in the urine, the antibody binding sites will become saturated and prevent attachment of the drug conjugate to the test trip. Therefore, the presence of the line on the test region indicates a negative result for the corresponding drug class, and the absence of the test line on the test region indicates a positive result for the corresponding drug class. Any faint line in the test region indicates a negative result. A visible line generated by a different antigen antibody reaction is also present at the control region of the test strip to serve as a built-in control. If the control line is not present after the test, the result is invalid. These cups incorporate test strips that detect d-amphetamine (AMP), barbiturates (BAR), benzodiazepines (BZO), cocaine metabolite (benzoylecgonine, COC), marijuana metabolite (11-nor-d9-THC-COOH, THC), methadone (MTD), dmethamphetamine (MET), oxycodone (OXY), opiates (OPI), and phencyclidine (PCP). The NexScreen cup also detects ecstasy (MDMA, 3,4 methylendioxymethamphetamine) and tricyclic antidepressants (TCA). The NexScreen cup and the DrugCheck Waive RT cup both include a temperature strip on the container to verify the specimen temperature. The DrugCheck Waive RT cup also includes a specimen validity strip to determine the specific gravity, pH and creatinine (semi-quantitative).
Urine specimen preparation
Residual urine, previously analyzed by ARUP Laboratories for one or more drugs, was obtained and de-identified according to protocols approved by the University of Utah Institutional Review Board. Drug-free urine was pooled and used as a matrix to create four multi-analyte spike samples that were used to evaluate the sensitivity, precision, accuracy and stability of the cups. Pure drug and drug metabolite standards obtained from Cerilliant (Round Rock, TX) were used to fortify the samples with the drug analytes of interest at concentrations of 0, 50, 100 and 150%, and, if needed, 25 or 200% of the manufacture's claimed cutoff . Four different drug spike samples were prepared to include the calibrator cited by the manufacturers and some commonly prescribed drugs that fall within the drug classes detected by the cups. Spike Sample I contained d-amphetamine, benzoylecgonine, methadone, morphine, oxazepam, secobarbital and THC. Spike Sample II contained codeine, 7-amino-clonazepam, d-methamphetamine, nortriptyline, phencyclidine and phenobarbital. Spike Sample III contained desipramine, MDMA, hydrocodone, 11-hydroxyalprazolam and methadone metabolite (EDDP, 2-ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium). Spike Sample IV contained 6-acetylmorphine, midazolam and oxycodone. The final concentration of each drug analyte was verified by validated in-lab quantitative confirmation testing [gas chromatography-mass spectrometry (GC-MS) or liquid chromatography -tandem mass spectrometry (LC -MS-MS)]. Spike samples were diluted as needed with residual drug-free urine. In addition to preparing a multiple-drug-spiked urine; acetaminophen, cyclobenzaprine, diphenhydramine, dextromethorphan and meprobamate were separately spiked to residual drug-free urine and evaluated for cross-reactivity.
To support specificity studies, 12 drug-positive patient pool samples were prepared from 56 residual urine samples. Urine samples were included based on results from validated in-lab quantitative confirmation testing (GC-MS or LC -MS-MS) and/ or qualitative screening based on full-scan GC -MS, representing 41 drug analytes ( parent drugs or drug metabolites).
Sensitivity, precision, accuracy, detection limit, specificity and stability Four replicates were tested for each drug class with each of the four spike samples at final concentrations approximating 0, 50, 100 and 150% of the published cutoff concentrations. Spike samples were designed to evaluate cross-reactivity within similar classes such as OPI -OXY, and AMP -MET-MDMA. Sensitivity, precision and accuracy were considered 100% if the drug was detected in all four cups, five min after urine was added to the cup for the NexScreen cup, and 10 min for the DrugCheck Waive RT cup, as described in the package insert. When sensitivity, precision and accuracy were 100% of spiked samples prepared to mimic 50% of the published cutoff concentrations, a second challenge was performed with four additional cups, using residual spike samples diluted with drug-free urine to approximate 25% of the published drug-specific cutoffs.
The limit of detection was defined as less than or equal to the lowest concentration that produced a positive result for all tested cups. When the limit of detection was greater than 150% of the published drug-specific cutoff, 200% of the published drug-specific cutoff was prepared for evaluation by using two additional cups.
To evaluate the stability of test results and the appropriate time to read the results, the cups were read after 5, 10, 15, 30, 60, 120 and 1440 min. The specificity of test results and crossreactivity were evaluated by reading the patient pooled samples and drug spiked urine samples.
Lot-to-lot comparison
A second lot of both NexScreen and DrugCheck Waive RT cups were evaluated using the spike sample set. Two cups of the second lot were tested with each of the four spike samples at each concentration (0-150% of published cutoff ).
Results
Sensitivity, precision, accuracy and detection limit Four replicates were tested for each drug class with each of the four spike samples, per approximate percentages of the published cutoff concentrations. Actual concentrations of the components of the spike samples were verified by LC-MS-MS or GC-MS. Table I shows the published cutoff concentrations and approximate detection limits observed for each drug analyte tested with the two products. The results for the observed cutoff concentrations are approximate, because they represent the concentration at which appropriate performance with four cups (100% accurate) was observed, but for which a lower concentration challenge did not produce accurate results in all four cups. Some questionable results were observed, particularly when the drug concentration was close to the cutoff concentration. Based on the manufacturer's instructions, any faint line in the test region was interpreted as negative. When 100% of the cups performed as expected when challenged with the lowest spike tested ( 25% of cutoff ), the observed cutoff concentration was listed as less than that concentration. When less than 100% of the cups were accurate when challenged with the highest concentration tested, the cutoff was listed as greater than that concentration.
The observed detection limits of all the drugs were lower than the manufacturer's claims for all drugs tested with the NexScreen cup, except MDMA. The detection limit of MDMA was slightly higher than the published cutoff of 500 ng/mL.
For the DrugCheck Waive RT cup, the observed detection limits for phenobarbital, benzoylecgonine, codeine and hydrocodone were 150, 167, 145 and 1,000 ng/mL, respectively, which are lower than manufacturer's claimed cutoff concentrations. For morphine and OXY, the detection limits were close to the manufacturer's published cutoff concentrations. The detection limit of secobarbital was approximately 150% of the manufacturer's published cutoff concentration. This cup did not detect 11-nor-d9-THC-COOH at concentrations up to 100 ng/ mL. The detection limits for AMP, MET and MTD approximated 200% of the manufacturer's published cutoff concentration. Oxazepam, a common urine metabolite of alprazolam (11-hydroxy-alprazolam) , and the heroin metabolite (6-acetylmorphine) were not detected by the concentrations utilized in this study with the DrugCheck Waive RT cup.
Neither the NexScreen cup nor the DrugCheck Waive RT cup detected a common urine metabolite of clonazepam (7-amino-clonazepam) at concentrations up to 856 ng/mL, or midazolam at concentrations up to 312 ng/mL. Both cups also failed to detect the common urine metabolite of methadone, EDDP, at concentrations up to 477 ng/mL. Spike samples were designed to evaluate cross-reactivity between OPI -OXY, and AMP-MET-MDMA. At the published cutoff concentrations (shown in parentheses), cross-reactivity was observed between OPI (300 ng/mL)-OXY (100 ng/mL) in the NexScreen cup, but no cross-reactivity was observed between AMP (1,000 ng/mL) -MET (1,000 ng/mL) -MDMA (500 ng/mL). The same cross-reactivity was not observed in DrugCheck Waive RT cup. In addition, no interference was observed in either cup, when challenged with 1,000 ng/mL of acetaminophen, diphenhydramine, dextromethorphen or meprobamate added to drug-free urine. The NexScreen cup claimed that 3,000 ng/mL of cyclobenzaprine will trigger a positive result in the TCA strip, but in practice, positive results were observed when urine samples were spiked with 1,000 ng/mL of cyclobenzaprine.
Stability
Following the manufacturers' instructions, the results for the NexScreen cup should be read at 5 min after urine is added to the cup, or at 10 min for the DrugCheck Waive RT cup. To determine how incubation time influences test results, cups used for the limit of detection study were read after 5, 10, 15, 30, 60, 120 and 1,440 min. The results for the NexScreen cups incubated with urine spiked with drugs at 100% of the published cutoffs are shown in Table II . Results were stable for at least one hour for all drug classes except MTD (one false negative at 15 min), MDMA (one false negative at 60 min) and 11-hydroxy-alprazolam (stable only for 5 min). The benzodiazepine assay was designed to detect oxazepam. This suggests that actual stability within a drug class will vary for individual drug analytes.
The DrugCheck Waive RT cup provides an indicator to show that the result is ready to read and another indicator to notify that the result is expired. According to the product literature, when the Result Ready window turns red, the result is acceptable. The manufacturer claimed that the result should be read after 10 min of incubation, and the red spot appeared between 5 and 10 min. When the Result Expired spot turned to red, usually after 15 min of incubation, the results should be considered invalid. Table III shows the result for DrugCheck Waive RT cups incubated with 100% of the published cutoff concentration for select analytes. Results that were positive were stable for 15 min for all drug classes except benzoylecognine (one false negative at 15 min) and morphine (one false negative at 15 min). Following the manufacturer's instructions, results should be read according to the indicator. These data also reflect the observation that the actual detection limits are significantly higher than those claimed by the manufacturer for most drug classes represented by the cup.
Specificity
The specific drug analytes known to be present in each of 12 patient urine pools and corresponding positive results are shown in Table IV . In all, there were 56 patient samples represented by the 12 patient pools that contained a total of 41 known drug compounds. No false negative results were observed with the NexScreen cup. In Samples 8 and 9, there were positive results for both OXY and OPI, which is consistent with the common crossreactivity between these two drug classes that was identified in the accuracy studies. False positives were observed in patient pool Sample 3 for BZO and Sample 10 for MTD, MET and TCA. The source of false positive results was not identified.
No false positive results were observed in the DrugCheck Waive RT cup. False negatives were observed in Sample 2 for butabital (BAR) and Sample 8 for MTD.
One strength and limitation of using patient specimens is the random concentration of drug metabolites. This study did not determine final concentrations of all drug metabolites likely to be present in the patient pools (e.g., glucuronide conjugates). Cross-reactivity of the metabolites may explain why some of the drugs gave positive results at concentrations below the limit of detection quantified using purified standards.
Lot-to-lot comparison
A second lot of the NexScreen and the DrugCheck Waive RT cups were evaluated, respectively. Only two cups were evaluated for each spiked concentration for the second lot of each cup. For the NexScreen cup, most of the results were identical, except MDMA and PCP. The detection limit of the MDMA in the second lot (111027) was 250 ng/mL, which is more sensitive than in the first lot (111020). An isolated false positive result was found for PCP in one cup of the second lot, but not the first lot.
In the DrugCheck Waive RT cup, there were several discrepancies between the two lots. The detection limit of BZO and morphine was 300 ng/mL for both drugs in the first lot (J12698). In the second lot (F11864), the detection limit was 150 ng/mL for both drugs. The second lot did not detect secobarbital when the concentration was 450 ng/mL. The J12698 lot showed one positive result from four cups when the hydrocodone was 450 ng/ mL, two positive results when the concentration was 300 ng/mL and no positive results when the concentration was 150 ng/mL. The second lot also detected hydrocodone when the concentration was greater than 150 ng/mL.
Discussion
The introduction of on-site urine drug testing has facilitated rapid drug tests convenient for use in emergency rooms, rehabilitation facilities and other clinical situations, including independent physicians' offices. However, a faster result is not necessarily an equivalent result to traditional laboratory testing in sensitivity or specificity. Pre-analytic, analytic and postanalytic factors can influence the quality of on-site testing and lead to misinterpretation.
Test results can be negatively affected by errors that occur in the pre-analytical phase. Possible sources of error include improper operation of the device, improper collection, patient misidentification, handling errors and adulteration. Urine can be diluted or substituted, or contain additives, including parent drugs. Monitoring the temperature is one way to evaluate the validity of the urine sample. If collected within minutes, the temperature range of urine should be between 90 and 1008F. In addition, the pH should be between 4.5 and 8, the specific gravity should be 1.003 to 1.030 and the creatinine should be 20 mg/dL or greater. Both urine testing cups evaluated in this study provide a temperature monitor strip. The DrugCheck Waive RT cup also provides creatinine, specific gravity and pH. The performance of the specimen validity strips was as expected.
Drug detection is based on the principles of competitive immunochemistry. The capability of a drug testing cup to detect a specific drug can vary according to the drug concentration in the urine and the cutoff concentration of the assay. Federally regulated testing is the most established use of urine drug testing, which mandates the detection of five drug classes (amphetamines/methamphetamines/methylenedioxymethamphetamine, cocaine, marijuana, opiates and phencyclidine), but the cutoff concentrations are too high and the included drug classes are too narrow for most clinical applications. Outside of federally regulated testing, there is little standardization among drug tests. The number of drug classes detected and the drug screen cutoff levels vary among manufacturers of urine drug testing devices and reagents. Controversies exist regarding the evaluation of the clinical value of immunoassay based urine drug testing. Multiple authors have provided different results when assessing the diagnostic accuracy. Manchikanti et al. (2, 3) systematically assessed the diagnostic accuracy based on 1,000 patients' urine samples and published a comparative evaluation of the accuracy of immunoassay with LC-MS-MS of urine drug testing of opioids, benzodiazepine and illicit drugs in chronic pain patients. Overall results showed a sensitivity of 92% and specificity of 93% for opioids with morphine, hydrocodone, codeine and hydromorphone. The numbers were better for MTD, with sensitivity of 96.1% and specificity of 98.8%. OXY and BZO had lower sensitivity, with 75.4 and 74.7% and better specificity of 92.3 and 98%. For illicit drugs, the sensitivity for cocaine was 25 and specificity was 100%. MET and AMP also had lower sensitivity with 40 and 47%, but higher specificity with 98.8 and 99.1%, respectively. The NexScreen and DrugCheck Waive RT cups evaluated in this study advertise the same cutoff concentrations for most of the detected drugs, yet performed quite differently when challenged. After titrating with spiked samples to evaluate and approximate the actual cutoff concentrations, the NexScreen cup demonstrated better sensitivity than claimed, whereas the DrugCheck Waive RT cups did not meet claims for AMP, MET, secobarbital, oxazepam, MTD and marijuana. In most cases, the immunoassay demonstrated adequate sensitivity but not specificity. This study shows that even FDA-cleared devices should be validated in-house to evaluate actual performance characteristics. Regarding specificity, cross-reactivity was observed between OPI (300 ng/mL) and OXY (100 ng/mL) in the NexScreen cup. No cross-reactivity was observed in the DrugCheck Waive RT cup. False positives were also observed with BZO, MET, MTD and TCA in the NexScreen cup. On the other hand, immunoassays may not equivocally identify a specific analyte and can result in false-negatives by missing compounds. Several false negative results were observed, particularly butabital (724 ng/mL), benzoylecgonine (cocaine metabolite, 127 ng/mL) and MTD (637 ng/mL) in the DrugCheck Waive RT cup. For some drug classes, such as BZO, sensitivity and specificity were variable for drugs within the class. The detection of clonazepam was particularly poor, which is consistent with other published findings (3, 4) . Therefore, it cannot be assumed that a drug for which performance is not specifically evaluated will be detected by a device that claims to detect a drug class. When sensitivity of the cup-based screen is lower than that published by the manufacturer, the confirmation method sensitivity may be too high to confirm a screen-positive result. This lack of coordination between screen and confirmation sensitivities can lead to apparent false positives, which can negatively impact patient care, if used to verify adherence to therapy. That is, a screen positive that fails to confirm and is used clinically to document adherence may affect access to therapy for the associated patient. As such, any screen-positive result that fails to confirm must be interpreted based on the clinical context and potential analytical limitations. Likewise, results that screen negative but were expected to be positive may benefit from analysis by a secondary, more sensitive method.
A practical aspect of implementing a point-of-collection drug testing device such as those described herein is archiving the results. A manual testing device has no computerized data capture or store function. The results must be observed and recorded manually at a certain period, due to the stability. This is a significant concern with the DrugCheck cup, which requires reading within a 5 -10 min window. The NexScreen cup results were stable for at least one hour in nearly all cases. Furthermore, the results wrap around the sides of the cup, making photo archiving impractical, and the interpretation sometimes will be subjective.
Several other on-site drug testing devices are available on the market and have been evaluated (5 -11), but most are not categorized as FDA cleared or CLIA-waived tests. Because CLIAwaived tests are defined as simple laboratory examinations and procedures, these tests do not require extensive training for office personnel and can be implemented without special licensing of the laboratory or personnel. The costs of pointof-collection drug testing devices may also qualify for payer reimbursement. On-site drug testing devices need to be used with caution, however, and actual performance characteristics must be understood. Additional testing by more specific and/or sensitive technology is recommended when results are inconsistent with clinical expectations (either positive or negative). Confirmatory testing is also important to investigate the specific drug responsible for a positive or negative result, to investigate dilute or suspicious samples and when quantitative data is required for interpretation. Liquid or gas chromatography -mass spectrometry techniques are preferred for confirmatory testing.
Conclusion
The analytical performance as defined by sensitivity, accuracy, precision, specificity, lot-to-lot comparison and stability of results generated with two on-site drug testing devices was evaluated: NexScreen cup and DrugCheck Waive RT cup. Overall, the NexScreen cups demonstrated better sensitivity than claimed, whereas the sensitivity of DrugCheck Waive RT cups did not meet claims. Specificity was a concern with both cups. Despite the advances in technology to produce more reliable results, on-site testing devices remain a screening tool. The simplicity of use and access to rapid results of the on-site drug testing can lead to serious medical or social consequences if unexpected results are not confirmed by secondary analysis. Appropriate interpretation of the results is crucial.
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